GKOS — Glaukos Corporation stock price, charts and financials

Latest market price

170.87

+4.15+2.49%

Overview Short InterestFilings

GKOSQT76Glaukos Corporation·NYSE

Overview Short InterestFilings

170.87+2.49%

Loading chart...

Signal & projected range

Earnings big beat — drift (PEAD)Historical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

BRKR+2.34%$64.31 MASI+0.00%$179.95 GMED+3.39%$81.46 BIO+2.84%$334.71 PODD+2.63%$169.70 ALGN+2.21%$172.89 PEN+0.57%$323.02 SNN+1.87%$32.15

Snapshot

Index	-	P/E	-	EPS (ttm)	-3.28	Insider Own	3.17%	Shs Outstand	58.98M	Perf Week	8.56%

Market Cap	9.83B	Forward P/E	-	EPS next Y	0.50	Insider Trans	-5.17%	Shs Float	56.62M	Perf Month	21.19%

Enterprise Value	9.82B	PEG	0.46	EPS next Q	-	Inst Own	-	Short Float	8.31%	Perf Quarter	16.04%

Income	-189.79M	P/S	16.05	EPS this Y	90.65%	Inst Trans	-	Short Ratio	4.77	Perf Half Y	40.02%

Sales	612.84M	P/B	14.27	EPS next Y	263.81%	ROA	-20.43%	Short Interest	4.70M	Perf YTD	47.66%

Book/sh	-	P/C	-	EPS next 5Y	-	ROE	-27.07%	52W High	188.58 -9.39%	Perf Year	77.27%

Cash/sh	-	P/FCF	-	EPS past 3/5Y	-	ROIC	-9.59%	52W Low	74.98 127.88%	Perf 3Y	119.48%

Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	21.45% 17.64%	Gross Margin	79.12%	Volatility	7.90% 4.80%	Perf 5Y	233.97%

Dividend TTM	-	EV/Sales	16.03	EPS Y/Y TTM	-18.41%	Oper. Margin	-13.13%	ATR (14)	7.96	Perf 10Y	393.25%

Dividend Ex-Date	-	Quick Ratio	4.46	Sales Y/Y TTM	44.13%	Profit Margin	-30.68%	RSI (14)	71.28	Recom	2.32

Dividend Gr. 3/5Y	-	Current Ratio	5.04	EPS Q/Q	18.18%	SMA20	7.51%	Beta	0.75	Target Price	186.00

Payout	0.00%	Debt/Eq	0.15	Sales Q/Q	41.12%	SMA50	20.64%	Rel Volume	1.00	Prev Close	166.72

Employees	1,094	LT Debt/Eq	0.21	Earnings	Nov 04	SMA200	42.22%	Avg Volume	1.03M	Price	170.87

IPO Date	Jun 25, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	35.87% 9.91%	Net Debt/EBITDA	0.08	Volume	1,032,016	Change	2.49%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Jul-30-26	Reiterated	Stifel Nicolaus	Hold	$175 → $190
Jul-30-26	Reiterated	Needham	Buy	$150 → $201
Jul-30-26	Reiterated	Wells Fargo	Overweight	$135 → $178
Jul-30-26	Reiterated	Piper Sandler	Overweight	$165 → $195
Jul-30-26	Reiterated	HC Wainwright & Co.	Buy	$168 → $195
Jul-30-26	Reiterated	Truist Securities	Buy	$180 → $215
Jul-16-26	Reiterated	Truist Securities	Buy	$145 → $180
Jul-13-26	Reiterated	BTIG	Buy	$162 → $164
Jul-06-26	Initiated	H.C	Buy	$168
Jun-17-26	Reiterated	Needham	Buy	$136 → $150

Latest News

Jul-30-26

Jul-30-2612:56PM

Glaukos Q2 Earnings Beat Estimates on iDose TR Growth, Stock Upzacks.com

11:13AM

Truist Securities Maintains Buy on Glaukos, Raises Price Target to $215Benzinga

12:05AM

Glaukos Q2 Earnings Call Highlightsmarketbeat.com

Jul-29-26

Jul-29-2611:31PM

Glaukos (GKOS) Reports Q2 Earnings: What Key Metrics Have to Sayzacks.com

09:53PM

Glaukos Corporation (GKOS) Q2 2026 Earnings Call Transcriptseekingalpha.com

07:26PM

Glaukos (GKOS) Reports Q2 Loss, Tops Revenue Estimateszacks.com

04:05PM

Glaukos Announces Second Quarter 2026 Financial Resultsbusinesswire.com

Jul-28-26

Jul-28-2601:33PM

Glaukos: A Further Guidance Hike On Revenues Could Spike Shares Post Q2 Releaseseekingalpha.com

Jul-27-26

Jul-27-2607:00AM

Glaukos Announces Completion of Patient Enrollment in 510(k) Pivotal Study for PRESERFLO™ MicroShuntbusinesswire.com

Jul-26-26

Jul-26-2604:29AM

Bank of New York Mellon Corp Sells 12,667 Shares of Glaukos Corporation $GKOSdefenseworld.net

Jul-21-26

Jul-21-2601:35PM

10 Health Care Stocks With Whale Alerts In Today’s SessionBenzinga

Jul-17-26

Jul-17-2608:43AM

Stifel Maintains Buy on Glaukos, Raises Price Target to $175Benzinga

Jul-14-26

Jul-14-2605:07PM

Glaukos CFO Alex Thurman Sells $1.6 Million in Stock. What Should Investors Do Now?fool.com

Jul-08-26

Jul-08-2605:03PM

Abbott Labs vs. Glaukos: Which Healthcare Stock Is a Better Buy in 2026?fool.com

03:05PM

GKOS Stock Up More Than 45% Since May-End: What's Driving the Rally?zacks.com

Company

Glaukos Corporation operates as an ophthalmic medical technology and pharmaceutical enterprise, primarily focused on pioneering novel therapies for glaucoma, corneal disorders, and retinal diseases. The company offers a range of micro-bypass stents, including iStent, iStent inject, and iStent inject W. These devices are designed to enhance aqueous humor outflow, being inserted during cataract surgery to treat mild-to-moderate open-angle glaucoma. Its promising product pipeline features iStent Infinite, a three-stent system intended for standalone use in patients with refractory glaucoma, as well as iDose TR, a targeted injectable implant that utilizes Glaukos's micro-scale device platform to deliver therapeutic levels of medication. The company distributes its products through a direct sales organization and a network of distributors, serving markets across the United States and internationally. Glaukos Corporation, founded in 1998, is headquartered in San Clemente, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	614	507	383	315	283	294	225	237	181
Cost of Goods Sold Incl. D&A	128	114	94	76	69	67	92	39	25
Gross Profit	485	393	289	239	214	227	133	198	156
Selling, General and Administrative Excl. Other	387	329	263	224	193	179	171	177	120
Research and Development	177	151	136	139	123	101	85	68	50
Other Operating Expense	1	0	13	5	-20	-20	1	4	-1
Operating Income	-80	-87	-122	-129	-82	-33	-124	-50	-13
Interest Expense	4	5	10	14	14	13	14	3	0
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	-107	-102	-13	9	-2	-3	5	3	1
Net Income Before Taxes	-193	-193	-146	-134	-98	-49	-132	-50	-12
Income Taxes	-5	-5	1	1	1	0	-12	-65	1
Consolidated Net Income	-188	-188	-146	-135	-99	-50	-120	15	-13
Net Income From Continuing Operations	-188	-188	-146	-135	-99	-50	-120	15	-13
Net Income	-188	-188	-146	-135	-99	-50	-120	15	-13
EPS (Recurring)	-3.25	-3.28	-2.77	-2.78	-2.09	-1.07	-2.70	0.41	-0.37
EPS (Basic, Before Extraordinaries)	-3.25	-3.28	-2.77	-2.78	-2.09	-1.07	-2.70	0.41	-0.37
EPS (Diluted)	-3.25	-3.28	-2.77	-2.78	-2.09	-1.07	-2.70	0.37	-0.37
EBITDA	-151	-146	-96	-82	-49	-1	-84	-38	-6
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	—	—	—	—	—	—	—	147.22	—
Price To Sales Ratio	16.14	12.69	20.75	12.11	7.25	6.95	14.72	8.50	10.86
Gross Margin	78.99	77.51	75.46	75.87	75.62	77.21	59.11	83.54	86.19
Operating Margin	-13.03	-17.16	-31.85	-40.95	-28.98	-11.22	-55.11	-21.10	-7.18
Net Margin	-30.62	-37.08	-38.12	-42.86	-34.98	-17.01	-53.33	6.33	-7.18
Shares Outstanding	58	57	53	48	47	46	44	37	35
Market Capitalization	9,910	6,436	7,947	3,816	2,053	2,044	3,311	2,015	1,966
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Thurman Alex R.	SVP & CHIEF FINANCIAL OFFICER	Jul 16 '26	Option Exercise	38.68	10,000	386,800	53,906	Jul 21
Thurman Alex R.	SVP & CHIEF FINANCIAL OFFICER	Jul 16 '26	Sale	160.00	10,000	1,600,000	43,906	Jul 21
Thurman Alex R.	SVP & CHIEF FINANCIAL OFFICER	Jul 09 '26	Sale	155.00	10,000	1,550,000	43,681	Jul 13
Thurman Alex R.	SVP & CHIEF FINANCIAL OFFICER	Jul 09 '26	Option Exercise	38.68	10,000	386,800	53,681	Jul 13
Thurman Alex R.	SVP & CHIEF FINANCIAL OFFICER	Jul 06 '26	Option Exercise	38.68	10,000	386,800	53,681	Jul 08
Thurman Alex R.	SVP & CHIEF FINANCIAL OFFICER	Jul 06 '26	Sale	150.00	10,000	1,500,000	43,681	Jul 08
Navratil Tomas	CHIEF DEVELOPMENT OFFICER	Jul 01 '26	Sale	139.06	716	99,567	87,634	Jul 08
Navratil Tomas	CHIEF DEVELOPMENT OFFICER	Jun 16 '26	Sale	130.68	1,537	200,855	88,833	Jun 18
Hoffmeister David F	Director	May 26 '26	Option Exercise	24.69	15,000	370,350	47,671	May 28
Kliman Gilbert H	Director	May 14 '26	Option Exercise	24.69	5,000	123,450	40,528	May 18
Kliman Gilbert H	Director	May 14 '26	Sale	140.76	5,000	703,800	35,528	May 18
Kliman Gilbert H	Director	May 11 '26	Sale	135.00	5,000	675,000	35,528	May 13
Kliman Gilbert H	Director	May 11 '26	Option Exercise	24.69	5,000	123,450	40,528	May 13
Gilliam Joseph E	PRESIDENT & COO	May 01 '26	Sale	143.54	19,573	2,809,508	73,419	May 04
WEN LEANA	Director	May 01 '26	Sale	143.35	1,700	243,695	19,739	May 04

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.